Scope and Claims Review of US Patent 8,598,185 (Tenofovir DF/Emtricitabine/Efavirenz Unitary Bilayer Tablet with Compartmentalized Surfactant)

US 8,598,185 claims a specific unitary, orally suitable, compartmentalized solid dose that places tenofovir DF in a first compartment and surfactant plus efavirenz in a physically discrete second compartment that is in physical contact with the first. The core technical boundary is not “a combination tablet,” but a two-compartment unitary design with defined excipients, manufacturing methods, layer geometry, unit weight, and performance equivalence. The claims are narrower than typical fixed-dose combination (FDC) formulations because they require both (i) compartmentalization with physical association in contact and (ii) placement of a surfactant (exemplified as sodium lauryl sulfate) in the efavirenz-containing compartment.

The landscape implications for freedom-to-operate (FTO) are straightforward: a designer can potentially avoid infringement by changing compartment structure (not discrete), removing/relocating the surfactant, using different dose form geometry (not layers), removing the required manufacturing features (if the asserted claim depends on them), or achieving non-equivalent exposure versus specific comparators (for the performance claim).

What does US 8,598,185 claim, and what is the practical scope of infringement?

Immediate claim construction (as written):
Claim 1 requires all elements:

Unitary dosage form (single physical article administered together).
Contains tenofovir DF in a first compartment.
Contains a surfactant and efavirenz in a second compartment.
The first and second compartments are physically discrete.
The compartments are associated with and in physical contact with each other.
Further comprises emtricitabine.

Key scope levers inside Claim 1

“Physically discrete” bars a design where tenofovir DF and efavirenz are fully intermingled within a single homogeneous matrix with no compartment boundary.
“In physical contact” bars designs where the compartments are separated by an insulating barrier that prevents physical contact (depending on how “contact” is interpreted).
The surfactant is not optional for Claim 1 if the claim is asserted in full: it must be in the efavirenz-containing compartment (Claim 1 states “surfactant and efavirenz in a second compartment”).
The placement of emtricitabine is not explicitly assigned to either compartment in Claim 1. It can be in either compartment or distributed, as long as the overall dosage form “further comprises emtricitabine.”

How do dependent claims narrow the design space?

Dependent claims add specific structural and process limitations:

Claim 2: compartments are layers. This is a stronger structural limitation than “discrete compartments” because it requires layer geometry.
Claim 3: suitable for oral administration (useful for product-type matching).
Claim 4: bilayer tablet weighing < ~2.5 g (including optional film coating). This is a quantitative, product-matching boundary.
Claim 5: second compartment produced by high shear wet granulation.
Claim 6: surfactant is specifically sodium lauryl sulfate (SLS) (if asserted, it requires that identity).
Claim 7: first compartment produced by dry granulation.
Claim 8: total amount of efavirenz + emtricitabine + tenofovir DF is > ~60% by weight of the unitary dosage form. This constrains excipient levels.
Claim 9: further comprises specified excipients: magnesium stearate, croscarmellose sodium, microcrystalline cellulose, hydroxypropyl cellulose.
Claim 10: specific approximate weight percentages for each listed component (a tight formulation fingerprint).
Claim 11: “provided to a patient upon oral administration at substantially the same AUC and Cmax as” FDA-approved products Truvada and Sustiva.
Claim 12: bilayer tablet weight about 1200 mg to 2300 mg including optional film coating.
Claim 13: layers oriented horizontally along the axis of the tablet.
Claim 14: container comprising the unit dosage form of Claim 1 and a desiccant.

Featured-snippet style bottom line

US 8,598,185 protects a specific unitary bilayer concept: tenofovir DF in a discrete first compartment and efavirenz with surfactant in a discrete second compartment, with the compartments layered, physically contacting, and manufactured with distinct granulation methods in certain dependent claims.

Which claim elements are most vulnerable to design-around, and which are hardest to avoid?

Hard-to-avoid elements (Claim 1 backbone)

Compartmentalization with physical contact: If a competitor’s product uses one homogeneous blend or uses a barrier that eliminates “physical contact,” it can avoid the core concept.
Surfactant located with efavirenz: Many FDC products omit SLS or use different surfactants; placing a surfactant with efavirenz in the same compartment is still required for Claim 1 infringement.

Easier design-around elements (dependent claim levers)

SLS identity (Claim 6): Removing SLS or using a different surfactant can avoid Claim 6, but not Claim 1 if “a surfactant” remains present in the efavirenz compartment.
Granulation method (Claims 5 and 7): Changing manufacturing steps can avoid those dependent claims without necessarily avoiding Claim 1 (unless the independent claim is asserted).
Bilayer weight and layer orientation (Claims 4, 12, 13): Changing total tablet mass or altering layer orientation can avoid those dependents.
Specific excipient set and percentages (Claims 9 and 10): Avoidable if a competitor uses different polymers/disintegrants/lubricants or different ranges.
Exposure equivalence (Claim 11): A performance claim is harder to assess without bioequivalence studies; it is also a litigation accelerant because it can be tested with clinical PK data.

How do the manufacturing limitations shape the infringement analysis (wet granulation vs dry granulation)?

Claims 5 and 7 tie manufacturing methods to compartment formation:

Second compartment: produced by high shear wet granulation (Claim 5).
First compartment: produced by dry granulation (Claim 7).

In practice, these are often the points where a challenger focuses:

If a competitor forms both compartments via the same granulation route, they may avoid infringement of Claims 5/7.
If they manufacture in a manner that still results in a second compartment made “by high shear wet granulation,” they risk those dependent claims.

However, infringement of Claim 1 does not require those methods. So method changes are only fully protective if the asserted claims are limited to dependents.

What formulation limitations are explicitly claimed (excipient list and weight-percent fingerprint)?

Core excipient list (Claim 9)

If asserted alongside Claim 1, Claim 9 requires inclusion of:

magnesium stearate
croscarmellose sodium
microcrystalline cellulose
hydroxypropyl cellulose

Tight weight percentages (Claim 10)

Claim 10 sets approximate weight percentages for:

efavirenz ~39%
tenofovir DF ~19%
emtricitabine ~13%
magnesium stearate ~2%
croscarmellose sodium ~7%
sodium lauryl sulfate ~1%
microcrystalline cellulose ~17%
hydroxypropyl cellulose ~2%

This is a strong formulation barrier because it is not just “includes excipients,” but “approximately at these ratios.” If a generic or licensee uses different amounts to hit tablet size constraints or stability targets, Claim 10 may not read on the formulation even if it reads on the bilayer concept.

What performance claim is protected: AUC/Cmax matching Truvada and Sustiva (Claim 11)?

Claim 11 adds a clinical exposure boundary:

The unitary dosage form must provide oral administration where AUC and Cmax are “substantially the same” as the exposure from Truvada and Sustiva.

This has two litigation-relevant impacts:

It invites PK comparison as an infringement and non-infringement tool.
It makes “equivalent but not identical” formulations risky because exposure can track formulation and manufacturing changes.

If a competitor argues non-infringement, it would typically confront the “substantially the same” language with comparative PK results, not chemistry-only arguments.

How narrow is the “bilayer tablet” and “weight” scope (Claims 4 and 12)?

Two weight constraints exist:

Claim 4: bilayer tablet weighing less than about 2.5 g.
Claim 12: bilayer tablet weighing about 1200 mg to 2300 mg.

These can matter if a competitor’s design changes tablet size to fit compression feasibility, coating needs, or stability-driven excipient loads.

Claim 13 further requires:

layers oriented horizontally along an axis of the tablet.

A competitor using vertical stacking, different compartment geometry, or different internal orientation could avoid dependent coverage even if it still makes a bilayer-like product.

Does the patent cover packaging and moisture protection (Claim 14 desiccant container)?

Claim 14 covers a:

container comprising the dosage form of Claim 1 and a desiccant.

This is common in stability-focused patent estates. For FTO, packaging claims are important because a product sold with desiccant-associated packaging can implicate Claim 14 even if the formulation is otherwise outside the tighter dependent claim boundaries.

A design-around for Claim 14 typically targets packaging architecture and whether a “desiccant” is included as claimed with the dosage form.

What parts of the claim set are likely to be asserted in litigation?

In US practice, plaintiffs often assert:

independent claim 1 to capture the concept
plus selected dependent claims to strengthen the claim match with formulation or manufacturing facts

Given this claim set, likely assertion paths include:

Claim 1 + Claim 2 (layers) if the competitor has a bilayer product concept.
Claim 1 + Claim 6 (SLS) if SLS is used as the surfactant.
Claim 1 + Claims 5 and 7 if manufacturing can be tied to high shear wet granulation for the efavirenz compartment and dry granulation for the tenofovir DF compartment.
Claim 1 + Claims 9/10 if the competitor’s formulation matches the excipient set and percentages.
Claim 1 + Claim 11 if there is a clinical PK equivalence target or the product is tested for bioequivalence against Truvada and Sustiva.

US Patent 8,598,185: scope map by claim element (quick matrix)

Claim element	Limitation	Infringement trigger for a competitor
Compartment design (Claim 1)	tenofovir DF in first compartment; surfactant + efavirenz in second	Must have discrete compartment separation and correct placement
Physical relationship (Claim 1)	compartments physically discrete but in contact	Must preserve “contact” across compartment boundary
Unit form (Claim 1)	unitary dosage form	Separate devices or kits reduce risk
Emtricitabine (Claim 1)	present in total unit	Must include emtricitabine somewhere in the dosage form
Layers (Claim 2)	compartments are layers	Must be layer geometry, not just discrete regions
Oral suitability (Claim 3)	oral administration suitable	Most solid oral tablets already satisfy
Bilayer weight cap (Claim 4)	< ~2.5 g	Tablet mass must be within bound
High shear wet granulation (Claim 5)	second compartment method	Manufacturing method match
Surfactant identity (Claim 6)	SLS	Requires SLS if asserted
Dry granulation (Claim 7)	first compartment method	Manufacturing method match
Dose loading (Claim 8)	API total > ~60 wt%	Excipient fraction must be low enough
Excipients (Claim 9)	specific excipient identities	Must include those exact excipients
Percentages (Claim 10)	approximate weight ratios	Formulation must align within “approximate” ranges
PK equivalence (Claim 11)	AUC/Cmax similar to Truvada + Sustiva	Requires PK match in bioequivalence-style metrics
Bilayer weight range (Claim 12)	~1200 to ~2300 mg	Mass must fall in range
Layer orientation (Claim 13)	horizontal along tablet axis	Requires specific internal orientation
Packaging (Claim 14)	container includes desiccant	Requires moisture-barrier packaging with desiccant

How does this patent fit into the broader “fixed-dose antiretroviral combination” patent landscape?

This claim set is a formulation and dosage form engineering patent rather than a pure drug substance patent. The novelty is the compartmentalized arrangement combining:

tenofovir DF (tenofovir prodrug)
efavirenz (NNRTI)
emtricitabine (NRTI) with a surfactant in the efavirenz compartment, plus defined manufacturing and tablet architecture.

Compared with standard FDC patents that cover simple blends, this one adds:

compartment boundary + physical contact requirement
layer orientation and weight constraints
method-of-manufacture constraints for certain compartments
packaging with desiccant
PK equivalence to specific reference products

In enforcement terms, this increases the difficulty for a generic to argue “different formulation” if the competitor replicates the compartment and layering architecture.

Key Takeaways

US 8,598,185 protects a unitary bilayer/compartmentalized oral tablet with tenofovir DF in one discrete compartment and efavirenz plus a surfactant in a physically discrete compartment that remains in physical contact with the first.
The independent claim (1) is broader conceptually than the dependents but still requires compartmentalization, physical contact, and placement of surfactant with efavirenz.
Dependent claims add high-impact barriers: layer geometry, tablet weight, layer orientation, granulation method, SLS surfactant identity, specific excipient sets and approximate percentages, PK equivalence, and desiccant-containing packaging.
For design-around and litigation risk, the highest-value scrutiny points are:
1. whether the competitor has true discrete compartments with physical contact
2. whether surfactant co-locates with efavirenz in the second compartment
3. whether formulation and manufacturing match the tight dependent claim filters (SLS, excipient ratios, granulation methods, PK equivalence)

FAQs

1) Does US 8,598,185 cover any fixed-dose combination of tenofovir DF, emtricitabine, and efavirenz in one tablet?
No. It requires the specific unitary compartment design with surfactant plus efavirenz in a discrete second compartment and tenofovir DF in a discrete first compartment that are physically discrete but in physical contact.

2) Can a competitor avoid infringement by removing sodium lauryl sulfate while keeping a surfactant?
That can avoid dependent Claim 6, but it does not avoid Claim 1 if a surfactant is still placed with efavirenz in the second compartment.

3) If a competitor uses a different tablet weight, does it avoid the patent?
It may avoid dependent Claims 4 and 12 if the tablet mass falls outside the claimed weight boundaries, but Claim 1 can still be asserted because Claim 1 does not include a weight limitation.

4) How does “substantially the same AUC and Cmax” affect infringement risk?
It creates a performance-based boundary that typically turns on comparative PK data. Products aiming for bioequivalence against Truvada and Sustiva are more likely to face this risk.

5) Does the patent cover packaging, not just the tablet formulation?
Yes. Claim 14 includes a container with a desiccant together with the claimed unit dosage form.

References

No references were provided or inferable from the prompt beyond the claim text itself.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	054060	⤷ Start Trial
Argentina	054511	⤷ Start Trial
Austria	E419839	⤷ Start Trial
Australia	2006257794	⤷ Start Trial
Australia	2006257795	⤷ Start Trial
Brazil	PI0611634	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,598,185

Which drugs does patent 8,598,185 protect, and when does it expire?

Summary for Patent: 8,598,185